Table 4.
Efficacy summary: clinical success at TOC
| Population | Solithromycin 800/400 mg |
Levofloxacin 750 mg |
||
|---|---|---|---|---|
| n/N (%)a | 95% CI | n/N (%) | 95% CI | |
| Co-primary efficacy variable | ||||
| ITT | 55/65 (84.6) | 73.5–92.4 | 58/67 (86.6) | 76.0–93.7 |
| CE | 46/55 (83.6) | 71.2–92.2 | 54/58 (93.1) | 83.3–98.1 |
| Micro-ITT | 14/18 (77.8) | 52.4–93.6 | 10/14 (71.4) | 41.9–91.6 |
| ME | 12/15 (80.0) | 51.9–95.7 | 10/13 (76.9) | 46.2–95.0 |
| Day 3, ITT (according to Biomarkers Consortium criteria) | 47/65 (72.3) | 59.8–82.7 | 48/67 (71.6) | 59.3–82.0 |
a
n, number of patients with clinical success; N, number of patients in the specified population; %, 100 × (n/N).